{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T20:38:24Z","timestamp":1795034304082,"version":"4.10.2"},"reference-count":31,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"17","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["J Clin Oncol"],"published-print":{"date-parts":[[2026,6,10]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Amivantamab, an EGFR-MET bispecific antibody with immune cell\u2013directing activity, is approved in non\u2013small cell lung cancer (NSCLC). Effective treatments are limited for chemorefractory metastatic colorectal cancer (mCRC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>\n                      OrigAMI-1 (ClinicalTrials.gov identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT05379595\">NCT05379595<\/jats:ext-link>\n                      ) is a phase Ib\/II study evaluating amivantamab monotherapy in chemorefractory (2-3 prior lines) mCRC. Participants had centrally confirmed\n                      <jats:italic toggle=\"yes\">RAS<\/jats:italic>\n                      \/\n                      <jats:italic toggle=\"yes\">BRAF<\/jats:italic>\n                      \/\n                      <jats:italic toggle=\"yes\">EGFR<\/jats:italic>\n                      ectodomain wild-type status, without\n                      <jats:italic toggle=\"yes\">ERBB2<\/jats:italic>\n                      \/\n                      <jats:italic toggle=\"yes\">HER2<\/jats:italic>\n                      amplification. Participants with left-sided mCRC without (cohort A) or with (cohort B) prior anti-EGFR antibody treatment, or right-sided mCRC (cohort C) regardless of prior anti-EGFR treatment, received intravenous amivantamab 1,050 mg (1,400 mg for \u226580 kg) once every 2 weeks. The primary end point was objective response rate (ORR) per RECIST v1.1.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>By October 31, 2024, 94 participants received amivantamab monotherapy (median follow-up, 11.9 months). The median age was 60 years, and 65% of participants were male, with a median of 2 prior lines (94%, prior bevacizumab). In left-sided cohorts, the ORR was 29% (5 of 17) in cohort A and 19% (10 of 54) in cohort B; the median duration of response (DoR) was 9.0 months and 6.1 months, and the median progression-free survival (PFS) was 5.7 months and 4.6 months, respectively. In the right-sided cohort, the ORR was 22% (10 of 23; 43% had prior anti-EGFR), the median DoR was 9.8 months, and the median PFS was 3.7 months. Most frequent treatment-related grade \u22653 adverse events (AEs) were rash (7%), dermatitis acneiform (4%), and hypoalbuminemia (4%). One participant discontinued amivantamab because of a treatment-related AE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Amivantamab monotherapy demonstrated promising, durable antitumor activity in chemorefractory mCRC, regardless of prior anti-EGFR therapy and the primary tumor location. The amivantamab safety profile in mCRC is consistent with experience in NSCLC. Amivantamab plus chemotherapy is currently being explored in two phase III studies in first-line and second-line mCRCs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco-25-02187","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T19:59:08Z","timestamp":1776801548000},"page":"1624-1634","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":8,"title":["Amivantamab Monotherapy in Chemorefractory\n                    <i>RAS<\/i>\n                    \/\n                    <i>BRAF<\/i>\n                    Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib\/II Study"],"prefix":"10.1200","volume":"44","clinical-trial-number":[{"clinical-trial-number":"nct05379595","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9758-7685","authenticated-orcid":true,"given":"Paul E.","family":"Oberstein","sequence":"first","affiliation":[{"name":"NYU Langone Health, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2277-4157","authenticated-orcid":true,"given":"J. Randolph","family":"Hecht","sequence":"additional","affiliation":[{"name":"UCLA Jonsson Comprehensive Cancer Center, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1311-4173","authenticated-orcid":true,"given":"Kanwal","family":"Raghav","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8530-8420","authenticated-orcid":true,"given":"Filippo","family":"Pietrantonio","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2392-599X","authenticated-orcid":true,"given":"Dirk","family":"Arnold","sequence":"additional","affiliation":[{"name":"Asklepios Tumorzentrum Hamburg, AK Altona, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6099-4236","authenticated-orcid":true,"given":"Victor","family":"Moreno","sequence":"additional","affiliation":[{"name":"START Madrid-FJD, Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6372-1230","authenticated-orcid":true,"given":"Eric","family":"Van Cutsem","sequence":"additional","affiliation":[{"name":"University of Leuven and University Hospitals Gasthuisberg, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9354-9550","authenticated-orcid":true,"given":"Rozita Abdul","family":"Malik","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5672-0072","authenticated-orcid":true,"given":"Yong Sang","family":"Hong","sequence":"additional","affiliation":[{"name":"Asan Medical Center, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1204-0574","authenticated-orcid":true,"given":"Myung Ah","family":"Lee","sequence":"additional","affiliation":[{"name":"Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1289-473X","authenticated-orcid":true,"given":"Harvey","family":"Yu-Li Su","sequence":"additional","affiliation":[{"name":"Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4911-6165","authenticated-orcid":true,"given":"Jeeyun","family":"Lee","sequence":"additional","affiliation":[{"name":"Samsung Medical Center, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreenivasa","family":"Chandana","sequence":"additional","affiliation":[{"name":"START Midwest, Grand Rapids, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia","family":"Cruz-Correa","sequence":"additional","affiliation":[{"name":"University of Puerto Rico Comprehensive Cancer Center and Pan American Center for Oncology Trials, San Juan, Puerto Rico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3922-9553","authenticated-orcid":true,"given":"Ying","family":"Yuan","sequence":"additional","affiliation":[{"name":"Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azura","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Beacon Hospital, Petaling Jaya, Selangor, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Ming","family":"Lai","sequence":"additional","affiliation":[{"name":"Changhua Christian Hospital, Changhua, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4719-4143","authenticated-orcid":true,"given":"Hung-Chih","family":"Hsu","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Linkou Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Taoyuan, Taiwan; School of Medicine, National Ching-Hua University, Hsinchu, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4581-8848","authenticated-orcid":true,"given":"Eric Xueyu","family":"Chen","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, University Health Network, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4653-6324","authenticated-orcid":true,"given":"Elena","family":"Elez","sequence":"additional","affiliation":[{"name":"Vall d\u2019Hebron University Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2573-5789","authenticated-orcid":true,"given":"Chia-Chi","family":"Lin","sequence":"additional","affiliation":[{"name":"National Taiwan University Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8901-741X","authenticated-orcid":true,"given":"Carlos","family":"Lopez","sequence":"additional","affiliation":[{"name":"Marqu\u00e9s de Valdecilla University Hospital, IDIVAL, UNICAN, Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8802-7352","authenticated-orcid":true,"given":"Hans","family":"Prenen","sequence":"additional","affiliation":[{"name":"Antwerp University Hospital, Edegem, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3915-4130","authenticated-orcid":true,"given":"Susana","family":"Rosell\u00f3-Ker\u00e4nen","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednico Universitario, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector","family":"Velez","sequence":"additional","affiliation":[{"name":"Ad-Vance Medical Research, Ponce, Puerto Rico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1485-1506","authenticated-orcid":true,"given":"Yu-Min","family":"Yeh","sequence":"additional","affiliation":[{"name":"National Cheng Kung University Hospital, Tainan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1349-3321","authenticated-orcid":true,"given":"Volker","family":"Heinemann","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Ludwig-Maximilians-Universit\u00e4t Klinikum, University of Munich, Comprehensive Cancer Center Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2335-0612","authenticated-orcid":false,"given":"Cathy","family":"Eng","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7036-3753","authenticated-orcid":true,"given":"Seung-Hoon","family":"Beom","sequence":"additional","affiliation":[{"name":"Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3281-8643","authenticated-orcid":true,"given":"Sabine","family":"Tejpar","sequence":"additional","affiliation":[{"name":"Department of Oncology, KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjib","family":"Chowdhury","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuesong","family":"Lyu","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Medha","family":"Kamat","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua C.","family":"Curtin","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharvin","family":"Patel","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Xie","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rianka","family":"Bhattacharya","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Schnepp","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2308-713X","authenticated-orcid":true,"given":"Emrullah","family":"Yilmaz","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Iwasawa","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh","family":"Daksh","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Lorenzini","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meena","family":"Thayu","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4456-8055","authenticated-orcid":true,"given":"Mahadi","family":"Baig","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han Sang","family":"Kim","sequence":"additional","affiliation":[{"name":"Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3275-431X","authenticated-orcid":true,"given":"Sae-Won","family":"Han","sequence":"additional","affiliation":[{"name":"Seoul National University Hospital and Seoul National University Cancer Research Institute, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_11_2_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071732"},{"key":"e_1_3_11_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.0106"},{"key":"e_1_3_11_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa071834"},{"key":"e_1_3_11_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.1620"},{"key":"e_1_3_11_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70118-4"},{"key":"e_1_3_11_7_2","doi-asserted-by":"publisher","DOI":"10.3747\/co.v17is1.616"},{"key":"e_1_3_11_8_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0558"},{"key":"e_1_3_11_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2022.11.004"},{"key":"e_1_3_11_10_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-20-0071"},{"key":"e_1_3_11_11_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-2833"},{"key":"e_1_3_11_12_2","volume-title":"RYBREVANT: RYBREVANT (amivantamab-vmjw) injection, for intravenous use [prescribing information]","year":"2024","unstructured":"RYBREVANT: RYBREVANT (amivantamab-vmjw) injection, for intravenous use [prescribing information]. Horsham, PA: Janssen Biotech; 2024"},{"key":"e_1_3_11_13_2","volume-title":"Rybrevant (amivantamab) 350 mg concentrate for solution for infusion [package insert]","author":"Rybrevant","year":"2024","unstructured":"Rybrevant: Rybrevant (amivantamab) 350 mg concentrate for solution for infusion [package insert]. Leiden, the Netherlands: Janssen Biologics B.V.; 2024"},{"key":"e_1_3_11_14_2","volume-title":"RYBREVANT (amivantamab injection) [package insert]","author":"RYBREVANT","year":"2025","unstructured":"RYBREVANT: RYBREVANT (amivantamab injection) [package insert]. Schaffhausen, Switzerland: Cilag AG; 2025"},{"key":"e_1_3_11_15_2","volume-title":"RYBREVANT intravenous infusion 350 mg [package insert]","author":"RYBREVANT","year":"2025","unstructured":"RYBREVANT: RYBREVANT intravenous infusion 350 mg [package insert]. Chiyoda-ku, Tokyo: Janssen Pharmaceutical K.K.; 2025"},{"key":"e_1_3_11_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.05.013"},{"key":"e_1_3_11_17_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0120"},{"key":"e_1_3_11_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy509"},{"key":"e_1_3_11_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00662"},{"key":"e_1_3_11_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.5437"},{"key":"e_1_3_11_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01690"},{"key":"e_1_3_11_22_2","unstructured":"Erbitux: Erbitux 5 mg\/mL solution for infusion [package insert]. Darmstadt Germany: Merck Healthcare KGaA"},{"key":"e_1_3_11_23_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0084"},{"key":"e_1_3_11_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01886-0"},{"key":"e_1_3_11_25_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-0859"},{"key":"e_1_3_11_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.6065"},{"key":"e_1_3_11_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-51981-5"},{"key":"e_1_3_11_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102023"},{"key":"e_1_3_11_29_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i28.6345"},{"key":"e_1_3_11_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx546"},{"key":"e_1_3_11_31_2","doi-asserted-by":"crossref","unstructured":"Pietrantonio F Ho GF Su Y-L et al: Amivantamab plus FOLFOX or FOLFIRI in metastatic colorectal cancer: Results from OrigAMI-1 a phase 1b\/2 study. Presented at ESMO Barcelona Spain September 13-17 2024","DOI":"10.1016\/j.annonc.2024.08.582"},{"key":"e_1_3_11_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.12.033"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO-25-02187","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T22:00:38Z","timestamp":1780696838000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO-25-02187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":31,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2026,6,10]]}},"alternative-id":["10.1200\/JCO-25-02187"],"URL":"https:\/\/doi.org\/10.1200\/jco-25-02187","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"2025-09-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-06","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}